Pfizer CEO Hank McKinnell will reschedule his Feb. 4 speech at the National Press Club after coming down with the flu. McKinnell was slated to speak on health care reform, but was likely to have also addressed - either through prepared remarks or during the question and answer session - the cardiovascular safety questions surrounding Pfizer's COX-2 inhibitors Celebrex and Bextra (1"The Pink Sheet" Jan. 3, 2005, p. 17). Pfizer says McKinnell caught the flu while traveling through southern Asia to assess the company's tsunami relief effort...
You may also be interested in...
FDA's caution on the use of COX-2 inhibitors leaves open the possibility for patients to use Pfizer's Celebrex and Bextra as first-line therapies
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.